In last trading session, Terns Pharmaceuticals Inc (NASDAQ:TERN) saw 0.75 million shares changing hands with its beta currently measuring -0.24. Company’s recent per share price level of $2.88 trading at $0.09 or 3.23% at ring of the bell on the day assigns it a market valuation of $251.53M. That closing price of TERN’s stock is at a discount of -295.83% from its 52-week high price of $11.40 and is indicating a premium of 35.07% from its 52-week low price of $1.87. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.87 million shares which gives us an average trading volume of 1.10 million if we extend that period to 3-months.
For Terns Pharmaceuticals Inc (TERN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.44. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.29 in the current quarter.
Terns Pharmaceuticals Inc (NASDAQ:TERN) trade information
Upright in the green during last session for gaining 3.23%, in the last five days TERN remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $2.88 price level, adding 11.93% to its value on the day. Terns Pharmaceuticals Inc’s shares saw a change of -48.01% in year-to-date performance and have moved -5.26% in past 5-day. Terns Pharmaceuticals Inc (NASDAQ:TERN) showed a performance of 28.57% in past 30-days. Number of shares sold short was 5.42 million shares which calculate 4.07 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 85.6% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 20. It follows that stock’s current price would drop -594.44% in reaching the projected high whereas dropping to the targeted low would mean a loss of -594.44% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 16.38% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -6.49% while estimates for its earnings growth in next 5 years are of -7.23%.
Terns Pharmaceuticals Inc (NASDAQ:TERN)’s Major holders
Insiders are in possession of 0.25% of company’s total shares while institution are holding 100.04 percent of that, with stock having share float percentage of 100.30%. Investors also watch the number of corporate investors in a company very closely, which is 100.04% institutions for Terns Pharmaceuticals Inc that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at TERN for having 7.62 million shares of worth $51.89 million. And as of 2024-06-30, it was holding 10.2326 of the company’s outstanding shares.
The second largest institutional holder is VIVO CAPITAL, LLC, which was holding about 6.18 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.3038 of outstanding shares, having a total worth of $42.11 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.07 shares of worth $5.97 million or 2.37% of the total outstanding shares. The later fund manager was in possession of 1.87 shares on Mar 31, 2025 , making its stake of worth around $5.38 million in the company or a holder of 2.14% of company’s stock.
